The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Sun., Apr. 26, 1:06 PM

Slide #20. SAGE Therapeutics Secondary Offering

Company: SAGE Therapeutics (NASDAQ:SAGE)
Date announced: 4/13/2015
Shares Offered: 2,285,714
Date of Pricing: 4/14/2015
Price Per Share: $52.50
Secondary Offering Details: SAGE Therapeutics (Nasdaq:SAGE) today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock. All of the shares in the offering are to be sold by SAGE. SAGE intends to grant the underwriters a 30-day option to purchase up to an additional $15 million of shares of common stock at the public offering price, less the underwriting discount. - updated 4/15 - SAGE Therapeutics (Nasdaq:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 2,285,714 shares of its common stock at a public offering price of $52.50 per share, before underwriting discounts. In addition, SAGE has granted the underwriters a 30-day option to purchase up to an additional 342,857 shares of common stock on the same terms and conditions.

Sage Therapeutics is a development stage company. Co. is a biopharmaceutical company focused on developing and commercializing medicines to treat life-threatening, rare central nervous system disorders. The product in Co.'s status epilepticus (SE) program, SAGE-547, is an intravenous agent in an adjunctive therapy, a therapy combined with therapeutic approaches, for the treatment of super-refractory SE. SE is diagnosed when a patient has a seizure lasting longer than five minutes, and is associated with substantial morbidity and mortality. SAGE-689 and SAGE-217, two additional product candidates in Co.'s SE program.
Open the SAGE Page at The Online Investor »

Company Name:  Sage Therapeutics Inc
Website:  www.sagerx.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding SAGE:  16
Total Market Value Held by ETFs:  $32.62M
Total Market Capitalization:  $1.54B
% of Market Cap. Held by ETFs:  2.12%
 

Open the SAGE Page at The Online Investor (in a new window) »

April 26, 2015    1:06 PM Eastern
Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
94th percentile
(ranked higher than approx. 94% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2015, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.